Renji Hospital

Company snapshot

Renji Hospital ([simplified Chinese](en.wikipedia.org/wiki/Simplified_Chinese): 仁济医院; [traditional Chinese](en.wikipedia.org/wiki/Traditional_Chines): 仁濟醫院; [pinyin](en.wikipedia.org/wiki/Pinyin): Rénjì Yīyuàn) is a general hospital in the [Pudong District](en.wikipedia.org/wiki/Huangpu_District,_) of Shanghai, China, with the rank of "Grade 3, Class A". The hospital is a [university hospital](en.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Renji Hospital. Not investment advice.

• What is Renji Hospital?

  RenJi Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include PCOS, Stomach Neoplasms. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO s

• Is Renji Hospital publicly traded?

  Renji Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Renji Hospital develop or market?

  We link 3 drug profile(s) where Renji Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/renji-hospital#company-drugs.

• What are the latest developments for Renji Hospital?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Renji Hospital focus on?

  Renji Hospital focuses on PCOS, Stomach Neoplasms based on our analysis of their pipeline programs and drug development activities.